Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health Inc. (NASDAQ:COSM) has successfully closed a registered direct offering of 2,828,320 shares of its common stock, alongside a private placement of warrants for the same number of shares, at a combined price of $11.50 per share. The total gross proceeds are approximately $32.5 million, which will be used for working capital and general corporate purposes. The offering included a $3 million investment from CEO Grigorios Siokas and other existing shareholders. The offering is conducted under a previously effective SEC registration statement.
Cosmos Health Inc. (Nasdaq:COSM) announced a registered direct offering and concurrent private placement for 2,828,320 shares of common stock at a purchase price of $11.50 per share, raising approximately $32.5 million before expenses. The offering includes warrants for the same number of shares, exercisable immediately at the same price, expiring in five years. Proceeds are intended for working capital and general corporate purposes, with closing expected on December 21, 2022. A.G.P./Alliance Global Partners is the sole placement agent.
Cosmos Holdings Inc. (NASDAQ: COSM) announced a 1-for-25 reverse stock split effective December 16, 2022, to comply with NASDAQ's minimum bid price requirement. This move was approved by the Board of Directors on December 15, following the Annual General Meeting on December 2. Additionally, the company is changing its name to Cosmos Health Inc. as part of its rebranding strategy. CEO Greg Siokas expressed optimism regarding the company's growth prospects and financial stability, emphasizing their focus on expanding as a global health and wellness company.
Cosmos Health, Inc. (NASDAQ:COSM) has engaged Shareholder Intelligence Services, LLC (ShareIntel) to analyze trading patterns of its stock over the last two years. This initiative underscores the company's commitment to transparency and shareholder value. ShareIntel provides compliance-driven tools to help companies monitor ownership and short selling activities. Cosmos Health specializes in nutraceuticals and pharmaceuticals, with a focus on R&D and global distribution. The company's diverse offerings and strategic expansions position it favorably in the healthcare market.
Cosmos Health, Inc. (Nasdaq: COSM) announced recent share activity, highlighting CEO Greg Siokas's participation in capital raises totaling $3M in 2022. The company raised $13.5M across two financing rounds and expects to reduce its debt by about 50% by year-end 2022. Siokas, who has invested over $10.6M in Cosmos since 2019, maintains a strong belief in the company's potential for growth and profitability. Management reaffirms confidence in the firm's financial strength and commitment to enhancing shareholder value.
Cosmos Health (NASDAQ:COSM) has commenced development for CCX0722, a groundbreaking obesity treatment utilizing biocompatible 3D spatial fillers derived from natural ingredients. This innovative product aims to enhance satiety and decrease appetite, with clinical trials scheduled for Q4 2023. Developed in collaboration with Cloudpharm, CCX0722 is positioned to address the increasing global demand for effective weight management solutions, projected to reach USD $132.7 billion by 2021, growing at a CAGR of 9.7% through the next decade.
Cosmos Health (NASDAQ: COSM) announced its appeal against a Nasdaq delisting due to a failure to maintain a minimum bid price of $0.10 per share. The company received a non-compliance letter on November 10, 2022, following a previous notice regarding its inability to meet a $1.00 per share requirement. Trading under Nasdaq will continue beyond November 21, 2022, as the company seeks a reverse stock split approval at its December 2, 2022, shareholder meeting. CEO Greg Siokas emphasized their commitment to remedying the situation for shareholders.
Cosmos Holdings (NASDAQ:COSM) reported Q3 2022 revenues of $12.0M, down from $13.6M in Q3 2021, primarily due to foreign exchange variations. Gross margins decreased to 14.8% from 17.3% year-over-year. Operating expenses were reduced by 34.7% to $2.1M. Adjusted EBITDA stood at $0.5M, down from $1.2M. The company raised $7.5M through a public offering and made significant strategic agreements, enhancing their market presence in healthcare distribution.
Cosmos Health, Inc. (NASDAQ:COSM) announced an exclusive agreement to distribute Nickelodeon's SpongeBob and PAW Patrol kids' vitamins in Greece and Cyprus. The vitamins, produced in the UK by ParkAcre, target preschool and slightly older children. CEO Greg Siokas expressed enthusiasm for the initial demand from major retailers, including pharmacies, and the strong marketing support from Nickelodeon. Cosmos aims to reach 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus, enhancing its distribution capabilities in the health and wellness market.
Cosmos Holdings (NASDAQ:COSM) announced a public offering of 62.5 million shares at $0.12 each, raising $7.5 million before expenses. The Series A and B Warrants accompany the shares, enabling investors to purchase additional stock. The funds will be used for acquisitions, settling liabilities, and general corporate needs. The closing date is anticipated around October 20, 2022. The offering is backed by A.G.P./Alliance Global Partners and follows an effective registration statement with the SEC.